Covaxin Dispatched to Various States Like Gujarat, Assam: Bharat Biotech
3 years, 7 months ago

Covaxin Dispatched to Various States Like Gujarat, Assam: Bharat Biotech

News 18  

Bharat Biotech on Friday said it has dispatched COVID vaccine Covaxin to various states like Gujarat, Assam, Tamil Nadu, Karnataka and Odisha. The Hyderabad-based vaccine major, which has come under fire from the Delhi government over supply-related issues, said it has also dispatched Covaxin lots to Kerala and Uttarakhand. thank all our employees @ BHarat bio who worked thru the holy month of Ramzan…” Bharat Biotech Co-Founder and Joint Managing Director Suchitra Ella said in a tweet. On May 12, Delhi Deputy Chief Minister Manish Sisodia said that Bharat Biotech has informed the state government that it cannot provide ’additional’ Covaxin doses to the national capital.

Kerala Uttarakhand Bharat Bharat Biotech Covaxin Bharat Bio  gujarat  ella  biotech  assam  bharat  vaccine  various  states  work  dispatched  uttarakhandcovaxin  covaxin  kerala

History of this topic

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
5 months, 1 week ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

The right way to counter a poor Covaxin safety study
5 months, 1 week ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 3 weeks ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
8 months, 1 week ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
2 years ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
2 years ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
2 years ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
2 years ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
2 years ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses
2 years ago

90L in city yet to get booster shot, but BMC has only 6K Covaxin doses

Hindustan Times  

Even as the country is bracing up for a possible surge in Covid-19 cases, the Brihanmumbai Municipal Corporation has only 6,000 Covaxin doses left while there have been no stocks of Covishield or Corbevax for the last few months. BMC’s executive health officer Dr Mangala Gomare said only 16% of the eligible population have received the booster dose and around …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years, 1 month ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Bharat Biotech misstated Covaxin trial data
2 years, 1 month ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 2 months ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 2 months ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 5 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 5 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 5 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 5 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here
2 years, 6 months ago

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here

Live Mint  

Biological E's Corbevax and Bharat Biotech's Covaxin on July 8 received the nod from the National Technical Advisory Group on Immunisation's Standing Technical Sub-Committee for use among children aged between 5-12 years. The Drugs Controller General of India granted emergency use authorisation to the Biological E's Corbevax for 5-12 year old and Bharat Biotech's Covaxin for minors belonging to the …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 6 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 6 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
2 years, 6 months ago

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

Firstpost  

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity Hyderabad: Bharat Biotech International Limited on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multi-centre …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 7 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 7 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds
2 years, 8 months ago

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

Deccan Chronicle  

New Delhi: The Subject Expert Committee of the Drug Controller General of India has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said. This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. However, the …

Govt panel approves use of Corbevax for 5-12 year age group
2 years, 8 months ago

Govt panel approves use of Corbevax for 5-12 year age group

India Today  

Expert panel of Drug Controller General of India -- India’s drug regulator-- has recommended granting emergency use authorisation for Biological E's Covid-19 vaccine Corbevax for children in 5 to 12 years age group. "The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E's EUA application has recommended granting emergency use authorisation for use of Corbevax in …

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO
2 years, 8 months ago

SII has stockpile of 200 mn doses; India better prepared to fight Covid: CEO

Hindustan Times  

Chief executive officer of Serum Institute of India Adar Poonawalla on Tuesday said the company has a stockpile of 200 million doses of Covishield, while it has already exported 40 million doses of Covovax to European countries and Australia. Serum Institute of India CEO Adar Poonawalla speaks at the 'AIMA Leadership Conclave' in New Delhi on Tuesday, "We have a …

Weighing the choices: on precautionary vaccine doses
2 years, 8 months ago

Weighing the choices: on precautionary vaccine doses

The Hindu  

As India sees a steady slump in its daily coronavirus count, the Centre has announced opening up the third, or ‘precautionary doses’, to everyone over 18 years. A major aspect of vaccines is the risk of adverse events following vaccination, and previous experience has suggested that certain vaccines may induce a higher risk of blood clots in younger populations. With …

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference
2 years, 9 months ago

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference

News 18  

A day after slashing the price of the precaution dose of Covishield to Rs 225 per shot for private hospitals, the Serum Institute of India told the Centre on Sunday that it will compensate for the price difference for the unexpired stocks lying with private centres in the form of free vials of fresh stocks, official sources said. Vaccine majors …

Covishield, Covaxin to now cost private hospitals Rs 225 per dose
2 years, 9 months ago

Covishield, Covaxin to now cost private hospitals Rs 225 per dose

India Today  

A single dose of the Serum Institute of India's Covishield and Bharat Biotech's Covaxin will now cost private hospitals Rs 225. Adar Poonawalla, CEO of SII, said in a tweet on Saturday that the vaccine maker has decided to slash the prices of the Covid-19 jab for private hospitals from Rs 600 to Rs 225 after consultation with the central …

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production
2 years, 9 months ago

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production

India Today  

In a setback to India’s indigenous vaccine against Covid-19, the World Health Organisation has issued a statement saying that the body is suspending the supply of Bharat Biotech’s Covaxin through UN agencies. A day earlier, Bharat Biotech issued a statement saying the company “announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply …

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies
2 years, 9 months ago

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies

India TV News  

Highlights The WHO has suspended the supply of Covaxin vaccine under the United Nations procurement The development comes after an inspection of the COVID-19 vaccine last month Earlier too, Bharat Biotech had said it is working on further improvements and upgrades Bharat Biotech has said it is working on upgrades to ensure that the production of Covaxin continues to meet …

WHO pauses Covaxin supply via UN bodies
2 years, 9 months ago

WHO pauses Covaxin supply via UN bodies

The Hindu  

Bharat Biotech to upgrade facility The World Health Organisation on Saturday suspended supply of Bharat Biotech’s COVID vaccine, Covaxin, to allow the manufacturer to upgrade facilities and address deficiencies found during an inspection last month. ‘Will meet standards’ In a statement issued on April 1, Bharat Biotech said it was fully committed to implementing facility improvements and upgrades to ensure …

WHO suspends Covaxin supply to UN agencies
2 years, 9 months ago

WHO suspends Covaxin supply to UN agencies

Deccan Chronicle  

Hyderabad: The World Health Organization has confirmed it has suspended the supply of Covaxin, produced by city-based Bharat Biotech, through UN procurement agencies and recommending to countries that received the covid vaccine to take actions as appropriate. A statement issued by WHO on Saturday said the suspension is in response to the outcomes of its post EUL inspection held between …

WHO suspends international supply of Covaxin via UN procurement
2 years, 9 months ago

WHO suspends international supply of Covaxin via UN procurement

India Today  

The World Health Organization in a statement issued on April 2 confirmed the suspension of supply of Covaxin produced by Bharat Biotech, through UN procurement agencies and gave recommendation to the countries that received the vaccine to take actions as appropriate. On April 1, the Indian vaccine manufacturer Bharat Biotech issued a statement announcing the “temporary slowing down of Covaxin …

Bharat Biotech temporarily slows down Covaxin production for facility optimisation
2 years, 9 months ago

Bharat Biotech temporarily slows down Covaxin production for facility optimisation

India Today  

Bharat Biotech on Friday announced it was temporarily slowing down production of its Covid-19 vaccine, Covaxin, across its manufacturing facilities for facility optimisation as it had already completed its supply obligations to procurement agencies and foresaw a decrease in demand. "For the coming period, the company will focus on pending facility maintenance, process, and facility optimisation activities," Bharat Biotech said …

Bharat Biotech says slowing down Covaxin production for facility optimisation
2 years, 9 months ago

Bharat Biotech says slowing down Covaxin production for facility optimisation

India TV News  

Highlights Bharat Biotech said it is temporarily slowing down production of its COVID-19 vaccine Covaxin. Company said 'will focus on pending facility maintenance, process, facility optimisation activities' Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement …

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group
2 years, 10 months ago

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group

News 18  

India’s central drug regulator on Wednesday granted emergency use authorisation to Serum Institute of India’s Covid-19 vaccine Covovax for the 12-17 age group subject to certain conditions. Confirming the DCGI approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted:"@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults …

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech
2 years, 10 months ago

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech

Firstpost  

The FDA has lifted its clinical hold on Bharat Biotech’s Investigational New Drug application to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States Hyderabad: Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States. “Ocugen, Inc announced that the US Food …

Covaxin to be evaluated as COVID-19 vaccine candidate in US, says Bharat Biotech
2 years, 10 months ago

Covaxin to be evaluated as COVID-19 vaccine candidate in US, says Bharat Biotech

India TV News  

Highlights Covaxin will be evaluated as a COVID-19 vaccine candidate in United States, Bharat Biotech said. COVAXIN will be evaluated as a COVID-19 vaccine candidate in the United States, said Bharat Biotech on Saturday. In a statement, Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, noted that the American health regulator -- the US Food and …

Covaxin granted emergency use approval in 13 countries, Govt informs Parliament
2 years, 11 months ago

Covaxin granted emergency use approval in 13 countries, Govt informs Parliament

India Today  

Covaxin has been granted Emergency Use Listing in 13 countries as on January 31 according to the WHO, Minister of State for Health Bharati Pravin Pawar informed the Lok Sabha on Friday. The COVID-19 Working Group of NTAGI recommended Covid vaccination in adolescents between 15 years to 18 years, Pawar said in a written reply. READ: Indian scientists create new …

Covishield, Covaxin get sale approval in India
2 years, 11 months ago

Covishield, Covaxin get sale approval in India

Deccan Chronicle  

New Delhi: The Drugs Controller-General of India on Thursday granted regular market approval for the Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for use in the adult population subject to conditions. As Covid-19 infections, driven by the Omicron variant, are still raging, with 407 districts reporting a positivity rate of over 10 per cent, the Centre on Thursday …

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials
2 years, 11 months ago

Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

India TV News  

Highlights Intranasal vaccine will be administered to those who have already taken their two-dose vaccine The interval between the second dose of Covid vaccine and booster dose will be six months According to Bharat Biotech, its nasal vaccine stimulates immune responses at the site of infection The Drugs Controller General of India has granted permission to Hyderabad-based biotechnology firm Bharat …

Covishield, Covaxin get conditional market nod
2 years, 11 months ago

Covishield, Covaxin get conditional market nod

Hindustan Times  

The Drugs Controller General of India, India’s pharmaceuticals regulator, granted a conditional market authorisation for Covishield and Covaxin, the two coronavirus vaccines widely used in the country, officials said on Thursday. “The @CDSCO_INDIA_INF has now upgraded the permission for Covaxin and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions,” …

Two COVID vaccines may cost Rs. 275 after market nod
2 years, 11 months ago

Two COVID vaccines may cost Rs. 275 after market nod

Deccan Chronicle  

NEW DELHI: In a bid to make vaccines against Covid-19 affordable, prices of Covishield and Covaxin jabs are likely to be capped at Rs 275 per dose, with an additional service charge of Rs 150. Serum Institute of India director Prakash Kumar Singh had submitted an application to the DCGI on October 25 seeking regular market approval for its Covishield …

Panel pitches full market nod for Covaxin, Covishield
2 years, 11 months ago

Panel pitches full market nod for Covaxin, Covishield

Hindustan Times  

The subject expert panel of the national drugs regulator on Wednesday recommended full market authorisation for both Covaxin and Covishield under certain conditions, according to people familiar with the developments. Serum Institute of India and Bharat Biotech International Ltd, manufacturers of Covishield and Covaxin respectively, separately applied to the central drugs standard control organisation to seek full market authorisation stating …

Discover Related